Trigemina Secures $4,500,000 Series A Funding Round

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    809B Cuesta Drive Mountain View, CA 94040
  • Company Description
    Trigemina, Inc. exploits a newly discovered pathway for targeting the central nervous system, enabling vast new opportunities for treating acute and chronic pain.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series A
  • Proceeds Purposes
    Proceeds for the Series A-1 round will be used to fund the completion of the Phase II TRIG-05 clinical trial evaluating the Company’s lead drug candidate, TI-001, an intranasal oxytocin therapy, for the treatment of chronic migraine.
  • M&A Terms
  • Venture Investor
    Aurus Bios Fund
  • Venture Investor

Trending on Xconomy